Currently, TNF-α inhibitory drugs such as the monoclonal antibodies infliximab and adalimumab (Richmond et al., 2015), and IL-6 receptor inhibitors such as the monoclonal antibody tocilizumab, and a monoclonal antibody against IL-1β anakinra are widely used in the clinical treatment of RA (Prieto-Peña and Dasgupta, 2021). The gene discussed is TNF; the disease is rheumatoid arthritis.